Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the treatment of
choice to consolidate remission in patients with poor-risk acute myeloid leukemia (AML) …

There was no consensus on whether prognostic advantages existed when transplant
conducted at first complete remission (CR1) stage than at second complete remission (CR2) …

Introduction: Diagnostic karyotype is one of the most important determinants of initial
response to treatment, remission duration and overall survival in Acute Myelogenous …

Background Post remission consolidation chemotherapy for AML is well established, but
publications have suggested the lack of necessity for post-remission therapy prior to …

In a pilot study, 75 patients with Primary Refractory (PRef) AML without matched family
donors were offered post-transplantation cyclophosphamide (PTCY) based haploidentical …

Background Allogeneic hematopoietic cell transplantation (allo‐HCT) is the only cure for
acute myeloid leukemia (AML) in second complete remission (CR2). Patients lacking a …

Background Autologous hematopoietic stem cell transplantation (auto-HSCT) is an
alternative choice for acute myeloblastic leukemia (AML) with intermediate-risk molecules …

Background. Optimal post-remission strategy for patients with acute myeloid leukemia (AML)
is still matter of debate. Allogeneic Stem Cell Transplant (allo-HSCT) is the most effective …

Pretransplant remission status in patients with acute myeloid leukemia (AML) is 1 of the most
important factors determining their outcomes after allogeneic hematopoietic cell …

Background Autologous stem cell transplantation (ASCT) has gained growing consideration
as a treatment option for favorable-risk acute myeloid leukemia (FR-AML) in first complete …